TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03046472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy treatment for Postural Behavior
Description: Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy treatment for Postural Behavior
Description: Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day.
Study: NCT02473393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPS-2071 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPS-2071 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPS-2071 tablet
Study: NCT01467596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elderly population, Middle aged population
Description: The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elderly population, Middle aged population
Description: The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
Study: NCT04006873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tezacaftor/Ivacaftor + Ivacaftor
Description: As per description in arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: As per description in arms
Study: NCT01546727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Family Intervention
Description: Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
Study: NCT02938845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total abdominal hysterectomy(TAH)
Study: NCT02378675

Intervention type: OTHER
Intervention: Blood draw
Description: During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.

Intervention type: OTHER
Intervention: Blood draw
Description: During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.
Study: NCT03439943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Description: Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).
Study: NCT03775291

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous assessment of sleep apnea by polysomnogram and wearable device
Description: Characterization of sleep apnea by lab-based polysomnogram

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous assessment of sleep apnea by polysomnogram and wearable device
Description: Characterization of sleep apnea by lab-based polysomnogram
Study: NCT03092271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care for Suicide Prevention
Description: ZSQI plus Stepped Care for Suicide Prevention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zero Suicide Quality Improvement
Description: ZSQI

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zero Suicide Quality Improvement
Description: ZSQI
Study: NCT02305888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204
Description: Treatment of actinic keratosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204
Description: Treatment of actinic keratosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204
Description: Treatment of actinic keratosis
Study: NCT01546727

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
Study: NCT00335556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT04194008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerivio
Description: A remote electrical neuromodulation (REN) device for the acute treatment of migraines.The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
Study: NCT03234608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AASPIRE Healthcare Toolkit
Description: The AASPIRE Healthcare Toolkit includes a variety of resources (information, worksheets, checklists, links) for patients and providers. The centerpiece of the toolkit is the Autism Healthcare Accommodations Tool, which allows a patient or their supporter to create a personalized accommodations report for the patient's provider. Intervention patients will use the toolkit and create an AHAT report. Intervention clinics will receive a copy of each patient's AHAT report, place it in the medical record, and share it with the patient's PCP and other staff.
Study: NCT01819064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: intravenous atropine affect on heart rate
Study: NCT00976170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC33(RO5137382)
Description: IV administration at 6 escalating dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Oral administration at 400mg twice daily or 400mg once daily
Study: NCT03862716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDegLira
Description: Dose is titrated to achieve fasting normoglycemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Dose is titrated to 2000 mg per day or maximal tolerated dose

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Therapy
Description: Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving
Study: NCT00335556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Patients undergo resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Patients undergo resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Patients undergo resection
Study: NCT03048461

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet Rich Plasma Prep System
Description: intradermal injections of platelet rich plasma to an area of alopecia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Prep System
Description: intradermal injections of platelet rich plasma to an area of alopecia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intradermal injections to an area of alopecia
Study: NCT02966873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) Treatment
Description: Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo Oral Capsule
Description: Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Description: Participants will be given the option to complete Functional magnetic resonance imaging (fMRI) at two timepoints (pre-treatment and end of treatment).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional magnetic resonance imaging (fMRI)
Description: Participants will be given the option to complete Functional magnetic resonance imaging (fMRI) at two timepoints (pre-treatment and end of treatment).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (MRS) Imaging
Description: Participants will be given the option to complete magnetic resonance spectroscopy (MRS) at two timepoints (pre-treatment and end of treatment).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Proton magnetic resonance spectroscopy (MRS) Imaging
Description: Participants will be given the option to complete magnetic resonance spectroscopy (MRS) at two timepoints (pre-treatment and end of treatment).
Study: NCT01462227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone High Dose
Description: Naltrexone 100mg for two administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Low Dose
Description: Naltrexone 50mg for two administrations.
Study: NCT00335556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Patients undergo resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Patients undergo resection
Study: NCT05143619

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT00942773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Study: NCT06710041

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotape
Description: Kinesiotape, when applied with a specific method and tension, significantly reduces the pressure on the median nerve by extending the transverse carpal ligament. It regulates edema under the skin and improves lymphatic and blood circulation. It reduces muscle spasms, eases the movement of tendons and fascia, and reduces pain through neurological suppression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Tendon and nerve gliding exercise

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Tendon and nerve gliding exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Tendon and nerve gliding exercise

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham taping
Description: In the sham taping group, kinesiotape was applied with two I bands without stretching and without having the proper position. This group was considered as the placebo group.
Study: NCT00942773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Study: NCT00335556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Patients undergo resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT03119038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine + epinephrine
Description: Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Intraoperative periarticular injection of 30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine Injection
Description: Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution
Study: NCT02951988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel pre-filled syringes for IV injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel pre-filled syringes for IV injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching Rapastinel
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study: NCT04520113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Household contact tracing
Description: Household contact tracing to test and diagnose Tuberculosis of household contacts of Tuberculosis patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Household contact tracing
Description: Household contact tracing to test and diagnose Tuberculosis of household contacts of Tuberculosis patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Household contact tracing
Description: Household contact tracing to test and diagnose Tuberculosis of household contacts of Tuberculosis patients.
Study: NCT06645158

Intervention type: DEVICE
Intervention: Transcutaneous bilirubin level monitoring
Description: self-monitoring by parents long-term: from birth to 30 days of age
Study: NCT01883128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body MRI
Description: Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Salvage Therapy
Description: Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
Study: NCT00335556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT01830387

Intervention type: DEVICE
Intervention: Polymetric clips
Description: The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump.

Intervention type: OTHER
Intervention: Endoscopic Staplers
Description: The study team will retrospectively identify patients who have undergone laparoscopic appendectomy by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
Study: NCT00335556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT00511199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRSP-EE
Description: Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
Study: NCT00335556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00797225

Intervention type: DRUG
Group type: OTHER
Intervention: Leuprorelin Acetate Depot
Description: Leuprorelin acetate depot injection 3.75 mg administered as an intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Elagolix
Description: Placebo tablet administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Elagolix
Description: Placebo tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Leuprorelin Acetate
Description: Saline solution administered as an intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Leuprorelin Acetate
Description: Saline solution administered as an intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Leuprorelin Acetate
Description: Saline solution administered as an intramuscular injection
Study: NCT03383211

Intervention type: OTHER
Intervention: RNAseq
Description: Transcriptome profiling of peripheral blood using RNA sequencing technology

Intervention type: OTHER
Intervention: RNAseq
Description: Transcriptome profiling of peripheral blood using RNA sequencing technology

Intervention type: OTHER
Intervention: RNAseq
Description: Transcriptome profiling of peripheral blood using RNA sequencing technology

Intervention type: OTHER
Intervention: RNAseq
Description: Transcriptome profiling of peripheral blood using RNA sequencing technology
Study: NCT04315922

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome and Plasma Characterisation
Description: Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome and Plasma Characterisation
Description: Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome and Plasma Characterisation
Description: Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing
Study: NCT02609503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable